A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004). (NCT06307431)
A Phase 2, Randomized, Double-blind, Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Participants With Renal Cell Carcinoma (INTerpath-004).
🩺 Plain-English Summary (8th-Grade Level)
The primary objective of the study is to compare intismeran autogene plus pembrolizumab to placebo plus pembrolizumab in participants with renal cell carcinoma (RCC) with respect to disease-free survival (DFS) as assessed by the investigator. The primary hypothesis is that intismeran autogene plus pembrolizumab is superior to placebo plus pembrolizumab with respect to DFS.
Who can join: Review the eligibility criteria below.
Location: City of Hope Comprehensive Cancer Center-Medical Oncology ( Site 0104) — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (63 Sites)
Showing the first 25 of 63 sites.
- City of Hope Comprehensive Cancer Center-Medical Oncology ( Site 0104) — Duarte, California
- UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro — Los Angeles, California
- UCSF Medical Center at Mission Bay ( Site 0108) — San Francisco, California
- Yale-New Haven Hospital-Yale Cancer Center ( Site 0102) — New Haven, Connecticut
- Beth Israel Deaconess Medical Center-Cancer Clinical Trials Office ( Site 0109) — Boston, Massachusetts
- Dana-Farber Cancer Institute-GU ( Site 0101) — Boston, Massachusetts
- Memorial Sloan Kettering Cancer Center ( Site 0100) — New York, New York
- Duke Cancer Institute ( Site 0106) — Durham, North Carolina
- Abramson Cancer Center ( Site 0107) — Philadelphia, Pennsylvania
- Fox Chase Cancer Center ( Site 0111) — Philadelphia, Pennsylvania
- UT Southwestern Medical Center ( Site 0110) — Dallas, Texas
- Hospital Británico de Buenos Aires-Oncology ( Site 1106) — Ciudad Autónoma de Buenos Aires, Buenos Aires
- Instituto Alexander Fleming-Alexander Fleming ( Site 1101) — Buenos Aires, Buenos Aires F.D.
- Asociación de Beneficencia Hospital Sirio Libanés ( Site 1110) — Buenos Aires, Buenos Aires F.D.
- Centro Privado de RMI Rio Cuarto ( Site 1104) — Río Cuarto, Córdoba Province
- Fundacion Estudios Clinicos ( Site 1111) — Rosario, Santa Fe Province
- Macquarie University-MQ Health Clinical Trials Unit ( Site 1502) — Macquarie University, New South Wales
- Westmead Hospital ( Site 1501) — Westmead, New South Wales
- Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Si — Brisbane, Queensland
- Fiona Stanley Hospital-Medical Oncology ( Site 1503) — Murdoch, Western Australia
- BC Cancer Vancouver ( Site 0005) — Vancouver, British Columbia
- CHU de Quebec - Université Laval - Hotel Dieu de Quebec ( Site 0008) — Québec, Quebec
- FALP-UIDO ( Site 1202) — Santiago, Region M. de Santiago
- Pontificia Universidad Catolica de Chile-Centro del Cáncer ( Site 1205) — Santiago, Region M. de Santiago
- Bradfordhill-Clinical Area ( Site 1201) — Santiago, Region M. de Santiago
📞 Contact the Study Coordinator
Phone: (800) 826-4673
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Renal Cell Carcinoma
- A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma — Birmingham, Alabama
- 89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma — Dallas, Texas
- Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma — Stanford, California
- Follow-up After Metastasectomy in Patients With Kidney Cancer — Houston, Texas
- Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma — La Jolla, California
- A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors — Los Angeles, California
Explore by condition: All Renal Cell Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.